These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16219319)

  • 1. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N; Kinoshita S; Inoue-Urakubo M; Kusunoki M; Iida S; Nakano R; Wakitani M; Niwa R; Sakurada M; Uchida K; Shitara K; Satoh M
    Biotechnol Bioeng; 2004 Sep; 87(5):614-22. PubMed ID: 15352059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides.
    Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K
    J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
    Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R; Sakurada M; Kobayashi Y; Uehara A; Matsushima K; Ueda R; Nakamura K; Shitara K
    Clin Cancer Res; 2005 Mar; 11(6):2327-36. PubMed ID: 15788684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
    Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
    MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.
    Okazaki A; Shoji-Hosaka E; Nakamura K; Wakitani M; Uchida K; Kakita S; Tsumoto K; Kumagai I; Shitara K
    J Mol Biol; 2004 Mar; 336(5):1239-49. PubMed ID: 15037082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
    Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.
    Kanda Y; Yamane-Ohnuki N; Sakai N; Yamano K; Nakano R; Inoue M; Misaka H; Iida S; Wakitani M; Konno Y; Yano K; Shitara K; Hosoi S; Satoh M
    Biotechnol Bioeng; 2006 Jul; 94(4):680-8. PubMed ID: 16609957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.
    Kanda Y; Imai-Nishiya H; Kuni-Kamochi R; Mori K; Inoue M; Kitajima-Miyama K; Okazaki A; Iida S; Shitara K; Satoh M
    J Biotechnol; 2007 Jun; 130(3):300-10. PubMed ID: 17559959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
    Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M; Iida S; Okazaki A; Mori K; Kitajima-Miyama K; Saitou S; Kakita S; Kanda Y; Shitara K; Kato K; Satoh M
    Glycobiology; 2009 Feb; 19(2):126-34. PubMed ID: 18952826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
    Masuda K; Kubota T; Kaneko E; Iida S; Wakitani M; Kobayashi-Natsume Y; Kubota A; Shitara K; Nakamura K
    Mol Immunol; 2007 May; 44(12):3122-31. PubMed ID: 17379311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
    Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.